The RPCI Pathology Resource Network (PRN) Shared Resource, directed by Dr. Carl Morrison (GN), provides specialized technologies, services, and expertise involving all aspects of biospecimens through 6 integrated facilities: 1) Tissue Procurement, 2) Pathology Core Facility, 3) Paraffin Archive, 4) Special Functions Laboratory, 5) Correlative Science Pathology Office (CSPO), and 6) Leukemia Bank. This centralization of all aspects of biospecimen research provides stability, reliability, cost-effectiveness, and quality control. The PRN utilizes a state-of-the-art Laboratory Information Management System (LIMS) to effectively manage tissue resources, and maintains the highest standards of quality control. The 34 full time faculty and staff (7 staff supported by CCSG funding) in the PRN provide key services, including: tissue procurement (MD leadership and 5 staff);state-of-the-art research histology (PhD leadership and 5 staff); archive curation and maintenance of formalin fixed paraffin-embedded (FFPE) tissue (2 staff);special laboratory functions including image scanning and analysis (1 PhD leader);tissue microarray (TMA) (1 staff);laser microdissection (1 staff);macromolecule processing (1 staff);spectral karyotyping (1 PhD leader, 1 staff;biospecimen clinical trials support (RN leadership and 5 staff);leukemia banking (MD leadership, 3 staff). Some staff have roles in more than one area. The (CSPO) is new since the last CCSG submission and provides an effective solution to the need for biospecimens and correlative science in clinical research. The PRN provides tissue biospecimens to more than 25 clinical trials on an annual basis and blood to almost all interventional studies. The PRN provides centralized equipment, including: immunohistochemistry autostainers, frozen tissue cryostats, freezer alarms and management systems, Aperio image scanning ScanScope, image analysis software, Arcturus and Leica tissue microdissection platforms. All of these are managed by the sophisticated multi-million dollar LIMS. Access to tissues at RPCI is determined by the various Disease Site Research Groups (DSRGs), but the overall guidelines are set by the Tissue Utilization Committee (TUC), in accordance with CCSG guidelines. The PRN provides services to multiple peer-review funded investigators and provides major contributions to The Cancer Genome Atlas [PI: Dr. Carl Morrison (GN)]. First priority for use is given to peer-review-funded RPCI CCSG members;second priority to non-peer-review- funded CCSG members;third priority to non-members and academic collaborators;and last priority to external users. During the reporting period, the PRN shared resource has served 85 members from 6 research programs, with 48% utilization by CCSG members with peer reviewed funding. The CCSG makes up 9% of the overall proposed budget.

Public Health Relevance

Biospecimens serve as the cornerstone of translational research for both non-human subject research and clinical trials. The PRN is nationally recognized for excellence in providing a full range of cost-effective, quality controlled tissue and biospecimen services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8933330
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
2014-06-26
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$71,552
Indirect Cost
$28,302
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Ciamporcero, Eric; Miles, Kiersten Marie; Adelaiye, Remi et al. (2015) Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 14:101-10
Ma, Yingyu; Hu, Qiang; Luo, Wei et al. (2015) 1?,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. J Steroid Biochem Mol Biol 148:166-71
Shen, Li; Sundstedt, Anette; Ciesielski, Michael et al. (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 3:136-48
Adelaiye, Remi; Ciamporcero, Eric; Miles, Kiersten Marie et al. (2015) Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther 14:513-22
Uekusa, Shota; Kawashima, Hiroyuki; Sugito, Kiminobu et al. (2014) Nr4a3, a possibile oncogenic factor for neuroblastoma associated with CpGi methylation within the third exon. Int J Oncol 44:1669-77
Ambrosone, Christine B; Zirpoli, Gary; Ruszczyk, Melanie et al. (2014) Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. Cancer Causes Control 25:259-65
Röhm, Marc; Grimm, Melissa J; D'Auria, Anthony C et al. (2014) NADPH oxidase promotes neutrophil extracellular trap formation in pulmonary aspergillosis. Infect Immun 82:1766-77
Rohrbach, Daniel J; Muffoletto, Daniel; Huihui, Jonathan et al. (2014) Preoperative mapping of nonmelanoma skin cancer using spatial frequency domain and ultrasound imaging. Acad Radiol 21:263-70
Ambrosone, Christine B; Young, Allyson C; Sucheston, Lara E et al. (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5:237-48
O'Brien, Shalana; Golubovskaya, Vita M; Conroy, Jeffrey et al. (2014) FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget 5:7945-59

Showing the most recent 10 out of 517 publications